% | $
Quotes you view appear here for quick access.

Omeros Corporation Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • dooper55 dooper55 Nov 8, 2012 9:02 AM Flag

    Omeros' Ophthalmology Product OMS302 Successful in Second Phase 3 Clinical Trial

    scubamoe, regarding funds on hand, don't forget the following from the last Q:

    "On July 2, 2012, we completed a public offering pursuant to which we sold 3,365,854 shares of our common stock at a price of $10.25 per share. After
    deducting underwriting discounts and other estimated offering expenses payable by us, our estimated net proceeds from the transaction were $32.4 million.
    We believe that our existing cash, cash equivalents and short-term investments and available capital under our committed equity line financing facility will be
    sufficient to fund our anticipated operating expenses, capital expenditures and note payments for at least the next 12 months. Our assumptions include our
    ability to raise capital under our $40.0 million equity line financing facility with Azimuth."

    SortNewest  |  Oldest  |  Most Replied Expand all replies
13.41+0.02(+0.15%)4:00 PMEDT